David Dai
Stock Analyst at UBS
(0.56)
# 3,782
Out of 4,829 analysts
20
Total ratings
20%
Success rate
-26.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Upgrades: Buy | $100 | $74.01 | +35.12% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.07 | +130.64% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $29.53 | -18.73% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $100.28 | -12.24% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.49 | +703.21% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $10.16 | +244.49% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $42.47 | +69.53% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $26.03 | +165.08% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $18.38 | +172.03% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $1.92 | +785.42% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $7.85 | +282.17% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $25.13 | +138.76% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $11.01 | +236.06% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.71 | +3,843.66% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $11.73 | +241.01% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.59 | +2,423.66% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.02 | +2,381.39% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $36.06 | +44.20% | 1 | Mar 17, 2020 |
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $74.01
Upside: +35.12%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.07
Upside: +130.64%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.53
Upside: -18.73%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $100.28
Upside: -12.24%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.49
Upside: +703.21%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $10.16
Upside: +244.49%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $42.47
Upside: +69.53%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $26.03
Upside: +165.08%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $18.38
Upside: +172.03%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $1.92
Upside: +785.42%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $7.85
Upside: +282.17%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $25.13
Upside: +138.76%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $11.01
Upside: +236.06%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.71
Upside: +3,843.66%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $11.73
Upside: +241.01%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.59
Upside: +2,423.66%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.02
Upside: +2,381.39%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $36.06
Upside: +44.20%